Protocol Single compound
SS-31
Elamipretide
Mitochondria-targeted tetrapeptide referenced in cardiolipin and mitochondrial research.
Compare side by side →Laboratory reference · in vitro research data
- Research vial sizes
- 10 mg · 50 mg
- Dosing data
- Not listed — reference entry covers vial concentration only.
- Storage
- Powder: 2–8 °C, or −20 °C for longer storage. After mixing with BAC water: 2–8 °C, use within about 4 weeks.
Reconstitution concentrations
Concentration per BAC-water volume; 10 units = 0.1 mL on a U-100 syringe.
| Vial | BAC water | mg/mL | mg per 10 u |
|---|---|---|---|
| 10 mg | 1 mL | 10 | 1 |
| 10 mg | 2 mL | 5 | 0.5 |
| 10 mg | 3 mL | 3.33 | 0.333 |
| 50 mg | 1 mL | 50 | 5 |
| 50 mg | 2 mL | 25 | 2.5 |
| 50 mg | 3 mL | 16.67 | 1.667 |
Calculate your vial
Draw to
—units
= — mL on a U-100 syringe
- Concentration
- —
- Per unit
- —
- Doses / vial
- —
Syringe
Research dossier · published literature summary
01
Mechanism of action
SS-31 (elamipretide) is a mitochondria-targeted tetrapeptide that binds cardiolipin in the inner mitochondrial membrane and is studied for stabilising mitochondrial energy production.
02
Observed research endpoints
- MMPOWER-3 (218 adults with primary mitochondrial myopathy, 24 weeks): no improvement vs placebo in 6-minute walk distance or fatigue.
- An earlier crossover trial missed its primary endpoint but showed signals in patient-reported outcomes, which supported MMPOWER-3.
03
Regulatory & safety context
- Not approved for mitochondrial myopathy; research-grade material is not a medicine.
- Generally well tolerated in trials; injection-site reactions were the most common event (80% in the crossover trial), mostly mild.
04
Citations
- Karaa A, et al. Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial. Neurology. 2023;101(3):e238–e252.2023-07Phase 3 randomized controlled trialRead paper ↗
- Karaa A, et al. A randomized crossover trial of elamipretide in adults with primary mitochondrial myopathy. J Cachexia Sarcopenia Muscle. 2020;11(4):909–918.2020Phase 2 randomized crossover trialRead paper ↗
Keep exploring
Where researchers source it
Listings are provided for reference — always verify the latest third-party COA before purchasing.
Medvinci Research
See siteFeatured supplier · third-party tested, COA published per batch
Supplier B
TBDPlaceholder — details coming soon
View productView COA
Supplier C
TBDPlaceholder — details coming soon
View productView COA